KIT and gastrointestinal stromal tumor: As a multi-target TKI, anlotinib has shown broader and stronger antitumor activity of in vitro studies than imatinib in KIT mutant GIST cells.7 As a reference, we compared to the phase 2 study of sunitinib, the median PFS of sunitinib second-line treatment in 61 patients was 8.0 months (95% CI, 3.7-12.2).